Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2‐D DIGE technology, we separate CSF proteins from patients with active MS and control subjects. Three of the seven differential proteins identified were related with complemen...
Saved in:
| Published in | Journal of cellular biochemistry Vol. 112; no. 7; pp. 1930 - 1937 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.07.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0730-2312 1097-4644 1097-4644 |
| DOI | 10.1002/jcb.23113 |
Cover
Loading…
| Abstract | Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2‐D DIGE technology, we separate CSF proteins from patients with active MS and control subjects. Three of the seven differential proteins identified were related with complement system, and the network analysis of the differential proteins revealed complement activation involvement in active MS. Complement C4b (gamma chain) was confirmed elevated by performing western blotting analysis (P < 0.01). The present results are an independent quantitative proteomic measure in CSF from active MS patients. The differential expression of the complement C4b and related proteins in CSF provides potential biomarkers as well as evidence for the involvement of complement activation in the pathogenesis of MS disease. J. Cell. Biochem. 112: 1930–1937, 2011. © 2011 Wiley‐Liss, Inc. |
|---|---|
| AbstractList | Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2-D DIGE technology, we separate CSF proteins from patients with active MS and control subjects. Three of the seven differential proteins identified were related with complement system, and the network analysis of the differential proteins revealed complement activation involvement in active MS. Complement C4b (gamma chain) was confirmed elevated by performing western blotting analysis (P < 0.01). The present results are an independent quantitative proteomic measure in CSF from active MS patients. The differential expression of the complement C4b and related proteins in CSF provides potential biomarkers as well as evidence for the involvement of complement activation in the pathogenesis of MS disease. Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2-D DIGE technology, we separate CSF proteins from patients with active MS and control subjects. Three of the seven differential proteins identified were related with complement system, and the network analysis of the differential proteins revealed complement activation involvement in active MS. Complement C4b (gamma chain) was confirmed elevated by performing western blotting analysis (P < 0.01). The present results are an independent quantitative proteomic measure in CSF from active MS patients. The differential expression of the complement C4b and related proteins in CSF provides potential biomarkers as well as evidence for the involvement of complement activation in the pathogenesis of MS disease.Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2-D DIGE technology, we separate CSF proteins from patients with active MS and control subjects. Three of the seven differential proteins identified were related with complement system, and the network analysis of the differential proteins revealed complement activation involvement in active MS. Complement C4b (gamma chain) was confirmed elevated by performing western blotting analysis (P < 0.01). The present results are an independent quantitative proteomic measure in CSF from active MS patients. The differential expression of the complement C4b and related proteins in CSF provides potential biomarkers as well as evidence for the involvement of complement activation in the pathogenesis of MS disease. Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2‐D DIGE technology, we separate CSF proteins from patients with active MS and control subjects. Three of the seven differential proteins identified were related with complement system, and the network analysis of the differential proteins revealed complement activation involvement in active MS. Complement C4b (gamma chain) was confirmed elevated by performing western blotting analysis ( P < 0.01). The present results are an independent quantitative proteomic measure in CSF from active MS patients. The differential expression of the complement C4b and related proteins in CSF provides potential biomarkers as well as evidence for the involvement of complement activation in the pathogenesis of MS disease. J. Cell. Biochem. 112: 1930–1937, 2011. © 2011 Wiley‐Liss, Inc. Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2-D DIGE technology, we separate CSF proteins from patients with active MS and control subjects. Three of the seven differential proteins identified were related with complement system, and the network analysis of the differential proteins revealed complement activation involvement in active MS. Complement C4b (gamma chain) was confirmed elevated by performing western blotting analysis (P<0.01). The present results are an independent quantitative proteomic measure in CSF from active MS patients. The differential expression of the complement C4b and related proteins in CSF provides potential biomarkers as well as evidence for the involvement of complement activation in the pathogenesis of MS disease. J. Cell. Biochem. 112: 1930-1937, 2011. ? 2011 Wiley-Liss, Inc. Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2‐D DIGE technology, we separate CSF proteins from patients with active MS and control subjects. Three of the seven differential proteins identified were related with complement system, and the network analysis of the differential proteins revealed complement activation involvement in active MS. Complement C4b (gamma chain) was confirmed elevated by performing western blotting analysis (P < 0.01). The present results are an independent quantitative proteomic measure in CSF from active MS patients. The differential expression of the complement C4b and related proteins in CSF provides potential biomarkers as well as evidence for the involvement of complement activation in the pathogenesis of MS disease. J. Cell. Biochem. 112: 1930–1937, 2011. © 2011 Wiley‐Liss, Inc. |
| Author | Yang, Mingchong Qin, Zhaoyu Lin, Chengzhao Liu, Shilian Qin, Yanjiang Li, Yun |
| Author_xml | – sequence: 1 givenname: Yun surname: Li fullname: Li, Yun organization: Institute of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan 250012, China – sequence: 2 givenname: Zhaoyu surname: Qin fullname: Qin, Zhaoyu organization: Laboratory of Systems Biology, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China – sequence: 3 givenname: Mingchong surname: Yang fullname: Yang, Mingchong organization: Institute of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan 250012, China – sequence: 4 givenname: Yanjiang surname: Qin fullname: Qin, Yanjiang organization: Department of Neurology, Qilu Hospital of Shandong University, Jinan 250012, China – sequence: 5 givenname: Chengzhao surname: Lin fullname: Lin, Chengzhao organization: Laboratory of Systems Biology, Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China – sequence: 6 givenname: Shilian surname: Liu fullname: Liu, Shilian email: liushilian@sdu.edu.cn organization: Institute of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan 250012, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21445879$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUFvFCEYhompsdvqwT9guKmHaWGAYTjqqtvaul40TbwQlvkmoTIwhRlt_73U3fVgqicO3_O84fveI3QQYgCEnlNyQgmpT6_t5qRmlLJHaEGJkhVvOD9ACyIZqcqgPkRHOV8TQpRi9RN0WFPORSvVAg3vXN9DgjA54zHcjglydjHg2GMbh9HDUGZ4THECFzJ2AduCb1LMowtF6f3sOtynOGBjJ_cD8DD7yRURZ-uhcC7j0UyuxOSn6HFvfIZnu_cYff3w_svyrLr8vDpfvrmsLFOCVb0wrW1lJ02nVN12tuPMtjWlhjXcCkWk2thONYbSjgrWg2JgBe2IUA2TtmbH6OU2t_z7ZoY86cFlC96bAHHOupWUtbwl9-Sr_5KUNZK3jDaioC926LwZoNNjcoNJd3p_zAKcbgFbts4Jem3dVDaPYUrGeU2Jvq9Ll7r077qK8fovYx_6ELtL_-k83P0b1B-Xb_dGtTVcnuD2j2HSd91IJoW-Wq80V-ur1beLtf7EfgG7d7Re |
| CitedBy_id | crossref_primary_10_1186_s12974_022_02404_2 crossref_primary_10_3390_diagnostics8030044 crossref_primary_10_1002_jcp_28583 crossref_primary_10_1007_s12035_012_8387_1 crossref_primary_10_3390_ijms23095162 crossref_primary_10_1002_jcb_23204 crossref_primary_10_1016_j_bbapap_2014_12_013 crossref_primary_10_1186_s12974_024_03036_4 crossref_primary_10_3389_fimmu_2022_1055050 crossref_primary_10_1016_j_clim_2016_04_003 crossref_primary_10_1371_journal_pone_0122048 crossref_primary_10_3389_fgene_2023_1076421 crossref_primary_10_3389_fnmol_2022_1017484 crossref_primary_10_3390_ijms22147377 crossref_primary_10_1007_s12026_017_8961_8 crossref_primary_10_1002_pmic_201500284 crossref_primary_10_1186_s13075_019_1846_6 crossref_primary_10_1186_s12974_015_0413_6 crossref_primary_10_1371_journal_pone_0153608 |
| Cites_doi | 10.1016/j.jneuroim.2006.07.009 10.1016/j.cca.2010.01.022 10.3109/08923979909007122 10.1016/j.jns.2007.01.065 10.1111/j.1365-2249.2008.03830.x 10.1034/j.1600-0404.2000.101002116.x 10.1007/s00216-005-3126-3 10.1016/j.jneuroim.2010.03.014 10.1016/j.jprot.2010.01.004 10.1212/01.wnl.0000342458.39625.91 10.1111/j.1445-5994.2009.02081.x 10.1093/brain/112.4.895 10.1002/pmic.200500083 10.1128/MCB.21.22.7817-7825.2001 10.1586/14789450.1.4.401 10.1093/hmg/ddq025 10.1586/epr.09.99 10.1016/S0162-3109(00)80299-4 10.1073/pnas.242603899 10.1007/s10571-007-9257-7 10.1016/j.jchromb.2004.06.044 10.1016/j.neurobiolaging.2003.11.003 10.1191/1352458504ms1023oa 10.1016/j.nbd.2009.04.010 10.1002/ana.21524 10.1016/S0140-6736(02)08220-X 10.1155/2005/806573 10.1111/j.1582-4934.2009.00850.x 10.1016/j.jneuroim.2009.10.019 10.1002/ana.1032 10.1093/brain/115.6.1611-a 10.1016/j.jns.2010.02.008 10.1016/0167-5699(96)20028-F 10.3181/00379727-136-35310 10.1074/mcp.M110.000877 10.1016/S0162-3109(00)80302-1 10.1080/00365510600863929 |
| ContentType | Journal Article |
| Copyright | Copyright © 2011 Wiley‐Liss, Inc. Copyright © 2011 Wiley-Liss, Inc. |
| Copyright_xml | – notice: Copyright © 2011 Wiley‐Liss, Inc. – notice: Copyright © 2011 Wiley-Liss, Inc. |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7X8 |
| DOI | 10.1002/jcb.23113 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef Neurosciences Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Biology |
| EISSN | 1097-4644 |
| EndPage | 1937 |
| ExternalDocumentID | 21445879 10_1002_jcb_23113 JCB23113 ark_67375_WNG_49NWGZKN_M |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Natural Science Foundation of China funderid: 81070952 |
| GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACIWK ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BLYAC BMNLL BMXJE BNHUX BROTX BRXPI BSCLL BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IH2 IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LH6 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NDZJH NF~ NNB O66 O9- OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RBB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 UB1 V8K W8V W99 WBKPD WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WSB WXSBR WYISQ XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~WT AAHQN AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7TK 7X8 |
| ID | FETCH-LOGICAL-c3953-f5a8c87d7ad9928dcd43c8211a364c59079bcd96a11d153fe93ec51d059637c23 |
| IEDL.DBID | DR2 |
| ISSN | 0730-2312 1097-4644 |
| IngestDate | Thu Jul 10 18:00:16 EDT 2025 Fri Jul 11 07:17:41 EDT 2025 Mon Jul 21 06:01:06 EDT 2025 Thu Apr 24 23:06:39 EDT 2025 Tue Jul 01 03:55:49 EDT 2025 Wed Jan 22 17:10:41 EST 2025 Wed Oct 30 09:54:48 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor Copyright © 2011 Wiley-Liss, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3953-f5a8c87d7ad9928dcd43c8211a364c59079bcd96a11d153fe93ec51d059637c23 |
| Notes | ArticleID:JCB23113 Natural Science Foundation of China - No. 81070952 ark:/67375/WNG-49NWGZKN-M istex:EC99FB93CFACA1BA89BABCAC9873932798B9220C ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| PMID | 21445879 |
| PQID | 1367483165 |
| PQPubID | 23462 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_871384802 proquest_miscellaneous_1367483165 pubmed_primary_21445879 crossref_citationtrail_10_1002_jcb_23113 crossref_primary_10_1002_jcb_23113 wiley_primary_10_1002_jcb_23113_JCB23113 istex_primary_ark_67375_WNG_49NWGZKN_M |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-07 July 2011 2011-07-00 2011-Jul 20110701 |
| PublicationDateYYYYMMDD | 2011-07-01 |
| PublicationDate_xml | – month: 07 year: 2011 text: 2011-07 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken |
| PublicationPlace_xml | – name: Hoboken – name: United States |
| PublicationTitle | Journal of cellular biochemistry |
| PublicationTitleAlternate | J. Cell. Biochem |
| PublicationYear | 2011 |
| Publisher | Wiley Subscription Services, Inc., A Wiley Company |
| Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company |
| References | Karp NA, Lilley KS. 2005. Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes. Proteomics 5: 3105-3115. Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. 2009. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 72: 602-608. Shaw C, Chapman C, Butzkueven H. 2009. How to diagnose multiple sclerosis and what are the pitfalls. Intern Med J 39: 792-799. Lilley KS, Friedman DB. 2004. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteom 1: 401-409. Loeffler DA, Camp DM, Schonberger MB, Singer DJ, LeWitt PA. 2004. Early complement activation increases in the brain in some aged normal subjects. Neurobiol Aging 25: 1001-1007. Zajicek JP, Wing M., et al. 1995. Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system. Lab Invest 73: 128-138. Hinman CL, Stevens-Truss R, Schwarz C, Hudson RA. 1999. Sequence determinants of modified cobra venom neurotoxin which induce immune resistance to experimental allergic encephalomyelitis: molecular mechanisms for immunologic action. Immunopharmacol Immunotoxicol 21: 483-506. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA. 2002. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA 99: 16899-16903. Liu S, Bai S, Qin Z, Yang Y, Cui Y, Qin Y. 2009. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med 13: 1586-1603. Chance MR, Chang J, Liu S, Gokulrangan G, Chen DH, Lindsay A, Geng R, Zheng QY, Alagramam K. 2010. Proteomics, bioinformatics and targeted gene expression analysis reveals up-regulation of cochlin and identifies other potential biomarkers in the mouse model for deafness in Usher syndrome type 1F. Hum Mol Genet 19: 1515-1527. Linington C, Morgan BP, Scolding NJ, Wilkins P, Piddlesden S, Compston DA. 1989. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 112: 895-911. Compston A, Coles A. 2002. Multiple sclerosis. Lancet 359: 1221-1231. Scott TF, Schramke CJ. 2010. Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. J Neurolog Sci 292: 52-56. Finehout EJ, Franck Z, Lee KH. 2005. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21: 93-101. Morgan BP, Gasque P. 1996. Expression of complement in the brain: role in health and disease. Immunol Today 17: 461-466. Jongen PJH, Doesburg WH, Ibrahim-Stappers JLM, Lemmens WAJG, Hommes OR, Lamers KJB. 2000. Cerebrospinal fuid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 101: 116-121. Yang YR, Liu SL, Qin ZY, Liu FJ, Qin YJ, Bai SM, Chen ZY. 2008. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barre syndrome. Cell Mol Neurobiol 28: 737-744. Wang L, Pan Y, Chen D, Xiao Z, Xi Z, Xiao F, Wang X. 2010. Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy. Clin Chim Acta 411: 581-583. Yuan X, Desiderio DM. 2005. Proteomics analysis of human cerebrospinal fluid. J Chrom B Anal Technol Biomed Life Sci 815: 179-189. Ingram G, Hakobyan S, Robertson NP, Morgan BP. 2010. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J Neuroimmunol 223: 124-127. Marouga R, David S, Hawkins E. 2005. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 382: 669-678. Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, Gilden DH. 2004. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Multiple Sclerosis 10: 245-260. Sahu A, Lambris JD. 2000. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49: 133-148. Iba K, Durkin ME, Johnsen L, Hunziker E, Damgaard-Pedersen K, Zhang H, Engvall E, Albrechtsen R, Wewer UM. 2001. Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity. Mol Cell Biol 21: 7817-7825. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. 2000. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49: 171-186. Ingram G, Hakobyan S, Robertson NP, Morgan BP. 2009. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol 155: 128-139. Vollmer T. 2007. The natural history of relapses in multiple sclerosis. J Neurol Sci 256(Suppl 1): S5-S13. Pabst H, Day NK, Gewurz H, Good RA. 1971. Prevention of experimental allergic encephalomyelitis with cobra venom factor. Proc Soc Exp Biol Med 136: 555-560. Ottervald J, Franzen B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellstrom S, Marko-Varga G, Vegvari A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T. 2010. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 73: 1117-1132. Rus H, Cudrici C, Niculescu F, Shin ML. 2006. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuroimmunol 180: 9-16. Stoevring B, Jaliashvili I, Thougaard AV, Ensinger C, Hogdall CK, Rasmussen LS, Sellebjerg F, Christiansen M. 2006. Tetranectin in cerebrospinal fluid of patients with multiple sclerosis. Scand J Clin Lab Investig 66: 577-583. Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska AM, Buydens L, Ampt K, Stingl C, Dane A, Muilwijk B, Luitwieler RL, Smitt PA, Hintzen RQ, Bischoff R, Wijmenga SS, Hankemeier T, van Gool AJ, Luider TM. 2010. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteom 9: 2063-2075. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK. 2009. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 35: 117-127. Sawai S, Umemura H, Mori M, Satoh M, Hayakawa S, Kodera Y, Tomonaga T, Kuwabara S, Nomura F. 2010. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis. J Neuroimmunol 218: 112-115. Zajicek JP, Wing M, Scolding NJ, Compston DA. 1992. Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain 115: 1611-1631. Barnett MH, Parratt JD, Cho ES, Prineas JW. 2009. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 65: 32-46. Jans H, Heltberg A, Zeeberg I, Halkjaer Kristensen J, Fog T, Raun NE. 1984. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Neurologica 69: 34-38. Tumani H, Lehmensiek V, Lehnert S, Otto M, Brettschneider J. 2010. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev Proteom 7: 29-38. Bai S, Liu S, Guo X, Qin Z, Wang B, Li X, Qin Y, Liu YH. 2009. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Mol Vis 15: 1638-1648. 1995; 73 2001; 50 1996; 17 2009; 65 2000; 49 1984; 69 1989; 112 2010; 19 2004; 25 2010; 223 2002; 99 2002; 359 2009; 155 2005; 21 1999; 21 2005; 815 2004; 1 2001; 21 2004; 10 2009; 13 2009; 35 2007; 256 2005; 382 2010; 218 2009; 72 2006; 66 2010; 411 2008; 28 1992; 115 2005; 5 1971; 136 2006; 180 2000; 101 2010; 292 2010; 7 2009; 15 2010; 73 2010; 9 2009; 39 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 e_1_2_6_37_1 Jans H (e_1_2_6_13_1) 1984; 69 e_1_2_6_21_1 e_1_2_6_20_1 e_1_2_6_40_1 e_1_2_6_9_1 Zajicek JP (e_1_2_6_41_1) 1995; 73 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_22_1 e_1_2_6_29_1 Bai S (e_1_2_6_2_1) 2009; 15 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 |
| References_xml | – reference: Pabst H, Day NK, Gewurz H, Good RA. 1971. Prevention of experimental allergic encephalomyelitis with cobra venom factor. Proc Soc Exp Biol Med 136: 555-560. – reference: Yuan X, Desiderio DM. 2005. Proteomics analysis of human cerebrospinal fluid. J Chrom B Anal Technol Biomed Life Sci 815: 179-189. – reference: Bai S, Liu S, Guo X, Qin Z, Wang B, Li X, Qin Y, Liu YH. 2009. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Mol Vis 15: 1638-1648. – reference: Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. 2000. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49: 171-186. – reference: Yang YR, Liu SL, Qin ZY, Liu FJ, Qin YJ, Bai SM, Chen ZY. 2008. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barre syndrome. Cell Mol Neurobiol 28: 737-744. – reference: Barnett MH, Parratt JD, Cho ES, Prineas JW. 2009. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 65: 32-46. – reference: Lilley KS, Friedman DB. 2004. All about DIGE: quantification technology for differential-display 2D-gel proteomics. Expert Rev Proteom 1: 401-409. – reference: Sawai S, Umemura H, Mori M, Satoh M, Hayakawa S, Kodera Y, Tomonaga T, Kuwabara S, Nomura F. 2010. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis. J Neuroimmunol 218: 112-115. – reference: Sahu A, Lambris JD. 2000. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology 49: 133-148. – reference: Linington C, Morgan BP, Scolding NJ, Wilkins P, Piddlesden S, Compston DA. 1989. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 112: 895-911. – reference: Jans H, Heltberg A, Zeeberg I, Halkjaer Kristensen J, Fog T, Raun NE. 1984. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Neurologica 69: 34-38. – reference: Scott TF, Schramke CJ. 2010. Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. J Neurolog Sci 292: 52-56. – reference: Hinman CL, Stevens-Truss R, Schwarz C, Hudson RA. 1999. Sequence determinants of modified cobra venom neurotoxin which induce immune resistance to experimental allergic encephalomyelitis: molecular mechanisms for immunologic action. Immunopharmacol Immunotoxicol 21: 483-506. – reference: Liu S, Bai S, Qin Z, Yang Y, Cui Y, Qin Y. 2009. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med 13: 1586-1603. – reference: Ingram G, Hakobyan S, Robertson NP, Morgan BP. 2010. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J Neuroimmunol 223: 124-127. – reference: Zajicek JP, Wing M, Scolding NJ, Compston DA. 1992. Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain 115: 1611-1631. – reference: Tumani H, Lehmensiek V, Lehnert S, Otto M, Brettschneider J. 2010. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev Proteom 7: 29-38. – reference: Wang L, Pan Y, Chen D, Xiao Z, Xi Z, Xiao F, Wang X. 2010. Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy. Clin Chim Acta 411: 581-583. – reference: Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA. 2002. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA 99: 16899-16903. – reference: Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, Gilden DH. 2004. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Multiple Sclerosis 10: 245-260. – reference: Karp NA, Lilley KS. 2005. Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes. Proteomics 5: 3105-3115. – reference: Compston A, Coles A. 2002. Multiple sclerosis. Lancet 359: 1221-1231. – reference: Loeffler DA, Camp DM, Schonberger MB, Singer DJ, LeWitt PA. 2004. Early complement activation increases in the brain in some aged normal subjects. Neurobiol Aging 25: 1001-1007. – reference: Vollmer T. 2007. The natural history of relapses in multiple sclerosis. J Neurol Sci 256(Suppl 1): S5-S13. – reference: McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127. – reference: Stoevring B, Jaliashvili I, Thougaard AV, Ensinger C, Hogdall CK, Rasmussen LS, Sellebjerg F, Christiansen M. 2006. Tetranectin in cerebrospinal fluid of patients with multiple sclerosis. Scand J Clin Lab Investig 66: 577-583. – reference: Finehout EJ, Franck Z, Lee KH. 2005. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21: 93-101. – reference: Chance MR, Chang J, Liu S, Gokulrangan G, Chen DH, Lindsay A, Geng R, Zheng QY, Alagramam K. 2010. Proteomics, bioinformatics and targeted gene expression analysis reveals up-regulation of cochlin and identifies other potential biomarkers in the mouse model for deafness in Usher syndrome type 1F. Hum Mol Genet 19: 1515-1527. – reference: Rus H, Cudrici C, Niculescu F, Shin ML. 2006. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuroimmunol 180: 9-16. – reference: Jongen PJH, Doesburg WH, Ibrahim-Stappers JLM, Lemmens WAJG, Hommes OR, Lamers KJB. 2000. Cerebrospinal fuid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 101: 116-121. – reference: Morgan BP, Gasque P. 1996. Expression of complement in the brain: role in health and disease. Immunol Today 17: 461-466. – reference: Marouga R, David S, Hawkins E. 2005. The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 382: 669-678. – reference: Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. 2009. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 72: 602-608. – reference: Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK. 2009. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 35: 117-127. – reference: Ottervald J, Franzen B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellstrom S, Marko-Varga G, Vegvari A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T. 2010. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 73: 1117-1132. – reference: Zajicek JP, Wing M., et al. 1995. Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system. Lab Invest 73: 128-138. – reference: Shaw C, Chapman C, Butzkueven H. 2009. How to diagnose multiple sclerosis and what are the pitfalls. Intern Med J 39: 792-799. – reference: Iba K, Durkin ME, Johnsen L, Hunziker E, Damgaard-Pedersen K, Zhang H, Engvall E, Albrechtsen R, Wewer UM. 2001. Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity. Mol Cell Biol 21: 7817-7825. – reference: Ingram G, Hakobyan S, Robertson NP, Morgan BP. 2009. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol 155: 128-139. – reference: Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska AM, Buydens L, Ampt K, Stingl C, Dane A, Muilwijk B, Luitwieler RL, Smitt PA, Hintzen RQ, Bischoff R, Wijmenga SS, Hankemeier T, van Gool AJ, Luider TM. 2010. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteom 9: 2063-2075. – volume: 815 start-page: 179 year: 2005 end-page: 189 article-title: Proteomics analysis of human cerebrospinal fluid publication-title: J Chrom B Anal Technol Biomed Life Sci – volume: 65 start-page: 32 year: 2009 end-page: 46 article-title: Immunoglobulins and complement in postmortem multiple sclerosis tissue publication-title: Ann Neurol – volume: 155 start-page: 128 year: 2009 end-page: 139 article-title: Complement in multiple sclerosis: its role in disease and potential as a biomarker publication-title: Clin Exp Immunol – volume: 223 start-page: 124 year: 2010 end-page: 127 article-title: Elevated plasma C4a levels in multiple sclerosis correlate with disease activity publication-title: J Neuroimmunol – volume: 25 start-page: 1001 year: 2004 end-page: 1007 article-title: Early complement activation increases in the brain in some aged normal subjects publication-title: Neurobiol Aging – volume: 39 start-page: 792 year: 2009 end-page: 799 article-title: How to diagnose multiple sclerosis and what are the pitfalls publication-title: Intern Med J – volume: 5 start-page: 3105 year: 2005 end-page: 3115 article-title: Maximising sensitivity for detecting changes in protein expression: experimental design using minimal CyDyes publication-title: Proteomics – volume: 13 start-page: 1586 year: 2009 end-page: 1603 article-title: Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis publication-title: J Cell Mol Med – volume: 17 start-page: 461 year: 1996 end-page: 466 article-title: Expression of complement in the brain: role in health and disease publication-title: Immunol Today – volume: 28 start-page: 737 year: 2008 end-page: 744 article-title: Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain‐Barre syndrome publication-title: Cell Mol Neurobiol – volume: 73 start-page: 1117 year: 2010 end-page: 1132 article-title: Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers publication-title: J Proteomics – volume: 112 start-page: 895 year: 1989 end-page: 911 article-title: The role of complement in the pathogenesis of experimental allergic encephalomyelitis publication-title: Brain – volume: 256 start-page: S5 issue: Suppl 1 year: 2007 end-page: S13 article-title: The natural history of relapses in multiple sclerosis publication-title: J Neurol Sci – volume: 73 start-page: 128 year: 1995 end-page: 138 article-title: Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system publication-title: Lab Invest – volume: 49 start-page: 133 year: 2000 end-page: 148 article-title: Complement inhibitors: a resurgent concept in anti‐inflammatory therapeutics publication-title: Immunopharmacology – volume: 69 start-page: 34 year: 1984 end-page: 38 article-title: Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis publication-title: Neurologica – volume: 35 start-page: 117 year: 2009 end-page: 127 article-title: Cerebrospinal fluid biomarkers in multiple sclerosis publication-title: Neurobiol Dis – volume: 411 start-page: 581 year: 2010 end-page: 583 article-title: Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy publication-title: Clin Chim Acta – volume: 136 start-page: 555 year: 1971 end-page: 560 article-title: Prevention of experimental allergic encephalomyelitis with cobra venom factor publication-title: Proc Soc Exp Biol Med – volume: 10 start-page: 245 year: 2004 end-page: 260 article-title: Proteomic analysis of multiple sclerosis cerebrospinal fluid publication-title: Multiple Sclerosis – volume: 292 start-page: 52 year: 2010 end-page: 56 article-title: Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later publication-title: J Neurolog Sci – volume: 115 start-page: 1611 year: 1992 end-page: 1631 article-title: Interactions between oligodendrocytes and microglia. A major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing publication-title: Brain – volume: 19 start-page: 1515 year: 2010 end-page: 1527 article-title: Proteomics, bioinformatics and targeted gene expression analysis reveals up‐regulation of cochlin and identifies other potential biomarkers in the mouse model for deafness in Usher syndrome type 1F publication-title: Hum Mol Genet – volume: 359 start-page: 1221 year: 2002 end-page: 1231 article-title: Multiple sclerosis publication-title: Lancet – volume: 21 start-page: 7817 year: 2001 end-page: 7825 article-title: Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity publication-title: Mol Cell Biol – volume: 101 start-page: 116 year: 2000 end-page: 121 article-title: Cerebrospinal fuid C3 and C4 indexes in immunological disorders of the central nervous system publication-title: Acta Neurol Scand – volume: 72 start-page: 602 year: 2009 end-page: 608 article-title: Demyelinating events in early multiple sclerosis have inherent severity and recovery publication-title: Neurology – volume: 21 start-page: 483 year: 1999 end-page: 506 article-title: Sequence determinants of modified cobra venom neurotoxin which induce immune resistance to experimental allergic encephalomyelitis: molecular mechanisms for immunologic action publication-title: Immunopharmacol Immunotoxicol – volume: 50 start-page: 121 year: 2001 end-page: 127 article-title: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis publication-title: Ann Neurol – volume: 7 start-page: 29 year: 2010 end-page: 38 article-title: 2D DIGE of the cerebrospinal fluid proteome in neurological diseases publication-title: Expert Rev Proteom – volume: 99 start-page: 16899 year: 2002 end-page: 16903 article-title: Generation and initial analysis of more than 15,000 full‐length human and mouse cDNA sequences publication-title: Proc Natl Acad Sci USA – volume: 1 start-page: 401 year: 2004 end-page: 409 article-title: All about DIGE: quantification technology for differential‐display 2D‐gel proteomics publication-title: Expert Rev Proteom – volume: 382 start-page: 669 year: 2005 end-page: 678 article-title: The development of the DIGE system: 2D fluorescence difference gel analysis technology publication-title: Anal Bioanal Chem – volume: 180 start-page: 9 year: 2006 end-page: 16 article-title: Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection publication-title: J Neuroimmunol – volume: 15 start-page: 1638 year: 2009 end-page: 1648 article-title: Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients publication-title: Mol Vis – volume: 218 start-page: 112 year: 2010 end-page: 115 article-title: Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis publication-title: J Neuroimmunol – volume: 49 start-page: 171 year: 2000 end-page: 186 article-title: Complement components of the innate immune system in health and disease in the CNS publication-title: Immunopharmacology – volume: 9 start-page: 2063 year: 2010 end-page: 2075 article-title: Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples publication-title: Mol Cell Proteom – volume: 21 start-page: 93 year: 2005 end-page: 101 article-title: Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease publication-title: Dis Markers – volume: 66 start-page: 577 year: 2006 end-page: 583 article-title: Tetranectin in cerebrospinal fluid of patients with multiple sclerosis publication-title: Scand J Clin Lab Investig – ident: e_1_2_6_26_1 doi: 10.1016/j.jneuroim.2006.07.009 – ident: e_1_2_6_37_1 doi: 10.1016/j.cca.2010.01.022 – volume: 15 start-page: 1638 year: 2009 ident: e_1_2_6_2_1 article-title: Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients publication-title: Mol Vis – ident: e_1_2_6_9_1 doi: 10.3109/08923979909007122 – ident: e_1_2_6_36_1 doi: 10.1016/j.jns.2007.01.065 – ident: e_1_2_6_11_1 doi: 10.1111/j.1365-2249.2008.03830.x – ident: e_1_2_6_14_1 doi: 10.1034/j.1600-0404.2000.101002116.x – ident: e_1_2_6_20_1 doi: 10.1007/s00216-005-3126-3 – ident: e_1_2_6_12_1 doi: 10.1016/j.jneuroim.2010.03.014 – ident: e_1_2_6_24_1 doi: 10.1016/j.jprot.2010.01.004 – ident: e_1_2_6_23_1 doi: 10.1212/01.wnl.0000342458.39625.91 – ident: e_1_2_6_30_1 doi: 10.1111/j.1445-5994.2009.02081.x – ident: e_1_2_6_17_1 doi: 10.1093/brain/112.4.895 – ident: e_1_2_6_15_1 doi: 10.1002/pmic.200500083 – ident: e_1_2_6_10_1 doi: 10.1128/MCB.21.22.7817-7825.2001 – ident: e_1_2_6_16_1 doi: 10.1586/14789450.1.4.401 – volume: 69 start-page: 34 year: 1984 ident: e_1_2_6_13_1 article-title: Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis publication-title: Neurologica – ident: e_1_2_6_4_1 doi: 10.1093/hmg/ddq025 – ident: e_1_2_6_35_1 doi: 10.1586/epr.09.99 – ident: e_1_2_6_28_1 doi: 10.1016/S0162-3109(00)80299-4 – ident: e_1_2_6_33_1 doi: 10.1073/pnas.242603899 – ident: e_1_2_6_38_1 doi: 10.1007/s10571-007-9257-7 – ident: e_1_2_6_39_1 doi: 10.1016/j.jchromb.2004.06.044 – ident: e_1_2_6_19_1 doi: 10.1016/j.neurobiolaging.2003.11.003 – ident: e_1_2_6_8_1 doi: 10.1191/1352458504ms1023oa – ident: e_1_2_6_34_1 doi: 10.1016/j.nbd.2009.04.010 – ident: e_1_2_6_3_1 doi: 10.1002/ana.21524 – ident: e_1_2_6_5_1 doi: 10.1016/S0140-6736(02)08220-X – ident: e_1_2_6_6_1 doi: 10.1155/2005/806573 – ident: e_1_2_6_18_1 doi: 10.1111/j.1582-4934.2009.00850.x – ident: e_1_2_6_27_1 doi: 10.1016/j.jneuroim.2009.10.019 – ident: e_1_2_6_21_1 doi: 10.1002/ana.1032 – ident: e_1_2_6_40_1 doi: 10.1093/brain/115.6.1611-a – ident: e_1_2_6_29_1 doi: 10.1016/j.jns.2010.02.008 – volume: 73 start-page: 128 year: 1995 ident: e_1_2_6_41_1 article-title: Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system publication-title: Lab Invest – ident: e_1_2_6_22_1 doi: 10.1016/0167-5699(96)20028-F – ident: e_1_2_6_25_1 doi: 10.3181/00379727-136-35310 – ident: e_1_2_6_32_1 doi: 10.1074/mcp.M110.000877 – ident: e_1_2_6_7_1 doi: 10.1016/S0162-3109(00)80302-1 – ident: e_1_2_6_31_1 doi: 10.1080/00365510600863929 |
| SSID | ssj0009932 |
| Score | 2.1183562 |
| Snippet | Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2‐D DIGE technology, we separate... Multiple sclerosis (MS) is a demyelinating disease of the central nervous system with complex immunopathogenesis. Using the 2-D DIGE technology, we separate... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1930 |
| SubjectTerms | 2-D DIGE Adult Biomarkers - cerebrospinal fluid Case-Control Studies Cerebrospinal fluid Complement Complement System Proteins - cerebrospinal fluid Complement System Proteins - genetics Electrophoresis, Gel, Two-Dimensional Female Gene Expression Humans Male Middle Aged Multiple sclerosis Multiple Sclerosis - cerebrospinal fluid Protein Interaction Mapping |
| Title | Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients |
| URI | https://api.istex.fr/ark:/67375/WNG-49NWGZKN-M/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcb.23113 https://www.ncbi.nlm.nih.gov/pubmed/21445879 https://www.proquest.com/docview/1367483165 https://www.proquest.com/docview/871384802 |
| Volume | 112 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB9KRfSlav3oWpUoIr7s9XaT3Cb4pKdtqfQexNIiQsjXwtnrXrm9g9q_3kn2o1RaEN_2YZYkk8nkN8nkNwBv0SSYKZ1JS1rolBXepkYalhrvqXTaSGfDje7hZLR_xA5O-MkafOjewjT8EP2BW1gZ0V-HBa5NvXNFGvrLmgGCk1ixNuRqBUD07Yo6CvfdeIOAFpyiWN6xCg3znf7Pa3vRnaDWi5uA5nXcGjee3Qfws-tyk29yOlgtzcBe_sXm-J9jeggbLSAlHxsLegRrvtqEu02Jyt-bcG_cVYR7DGef22oq6BVmxF-0ObQVmZckpqbHo0YSqR-mVU2mFbEobhahNklopJytpo6EFy1ERz9LunxGUmPjKDetScv0Wj-Bo90v38f7aVuuIbVUcpqWXAsrCldoJ2UunHWMWoEBpqYjZjlG4dJYJ0c6yxz62dJL6i3PXCgARAub06ewXs0rvwUEQavmnDuN4SfTwXjywmWsNJIhXhXDBN53E6dsy2UeSmrMVMPCnCvUpIqaTOBNL3reEHjcJPQuzn4voRenIeOt4Op4sqeYnBzv_fg6UYcJvO7MQ6Hyw-WKrvx8VatAfccEzUY8AXKLDAanVDAxzBN41phW32BgruOikDiyaCC391UdjD_Fj-f_LroN95uz8JBm_ALWl4uVf4lgamlexVXzB4PoGyw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZaxRBEC5CgsQXj3hNvFoR8WU2O9PdO9Pgi64ma5KdB0lIEKTpa2DNZlb2gOivt7rnCJEExLd5qKGv6uqq6urvA3iDKsF0aXVc0kzFLHMm1kKzWDtHhVVaWONvdMfFYHTM9k_56Rq8b9_C1PgQXcLN74xgr_0G9wnpnUvU0B9G99A78ZS1G57ROwRUXy_Bo_DkDXcIqMMxyqUtrlA_3el-vXIabfiJvbjO1bzquYajZ_cufG87XVecnPVWS90zv__Cc_zfUd2DO41PSj7USnQf1ly1BbdqlspfW7A5bEnhHsD5p4ZQBQ3DlLiLpoy2IrOShOr0kG0kAf1hUi3IpCIGxfXc05P4RsrpamKJf9RCVDC1pC1pJAtsHOUmC9KAvS4ewvHu56PhKG4YG2JDBadxyVVu8sxmygqR5tZYRk2OMaaiA2Y4BuJCGysGKkksmtrSCeoMT6znAKKZSekjWK9mlXsCBP1WxTm3CiNQprz-pJlNWKkFQ5c170fwrl05aRo4c8-qMZU1EHMqcSZlmMkIXneiP2sMj-uE3obl7yTU_MwXvWVcnhR7koniZO_bQSHHEbxq9UPi5Pv7FVW52WohPfody2ky4BGQG2QwPqU5y_tpBI9r3eoa9OB1PM8EjixoyM19lfvDj-Fj-99FX8Lm6Gh8KA-_FAdP4XadGvdVx89gfTlfuefoWy31i7CF_gAfEh9H |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEB5CQo-XHunlnmoppS_erC3JluhTu9tNmjSmlIaEUBC6DNtsvWG9C2l_fSX5CCkJlL75YYyk0afRjDT6BuC1gwRRpVFxiXMZk9zqWHFFYmUt5kYqbrS_0d0vsp0DsntEj9bgXfcWpuGH6A_c_MoI9tov8FNTbp2Thv7QauCcE1-xdoNkQ-YhPf56zh3lNt5wheAgHDu5tKMVGqZb_a8XNqMNr9ezyzzNi45r2Hkmt-F71-cm4eRksFqqgf79F53jfw7qDtxqPVL0voHQXViz1SZca2pU_tqEG6OuJNw9-Dluy6k4szBD9qxNoq3QvEQhNz2cNaLA_TCtajStkHbiauGLk_hGytlqapB_0oJkMLSoS2hEtWvcyU1r1FK91vfhYPLx22gnbus1xBpziuOSSqZZbnJpOE-Z0YZgzVyEKXFGNHVhOFfa8EwmiXGGtrQcW00T4ysA4Vyn-AGsV_PKPgLkvFZJKTXSxZ9EevSkuUlIqThxDisbRvC2mzihWzJzX1NjJhoa5lQ4TYqgyQhe9aKnDYPHZUJvwuz3EnJx4lPecioOi21BeHG4fbxXiP0IXnbwEE75_nZFVna-qoXnviMMJxmNAF0h46JTzAgbphE8bKDVN-ip6yjLuRtZAMjVfRW7ow_h4_G_i76A61_GE_H5U7H3BG425-I-5fgprC8XK_vMOVZL9TwsoD_KqR3_ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Differential+expression+of+complement+proteins+in+cerebrospinal+fluid+from+active+multiple+sclerosis+patients&rft.jtitle=Journal+of+cellular+biochemistry&rft.au=Li%2C+Yun&rft.au=Qin%2C+Zhaoyu&rft.au=Yang%2C+Mingchong&rft.au=Qin%2C+Yanjiang&rft.date=2011-07-01&rft.issn=1097-4644&rft.volume=112&rft.issue=7&rft.spage=1930&rft.epage=1937&rft_id=info:doi/10.1002%2Fjcb.23113&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0730-2312&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0730-2312&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0730-2312&client=summon |